Program
enzalutamide
Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.
Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 313 open or running | phase 4since Oct 31, 2013 | Jan 18, 2011 | Apr 30, 2027phase 1 · NCT07783282 |
| Pfizer | 162 open or running | phase 4since Nov 18, 2013 | Jul 31, 2007 | none ahead |
| Hinova Pharmaceuticals | 41 open or running | phase 3since Feb 17, 2019 | Dec 11, 2018 | none ahead |
| Alessa Therapeutics | 11 open or running | phase 1since Dec 14, 2023 | Dec 14, 2023 | Dec 30, 2028phase 1 · NCT06257693 |
| Applied Biology | 10 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| hinova-pharmaceuticals-usa-inc | 10 open or running | phase 3since Feb 20, 2019 | Feb 20, 2019 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Johnson & Johnson, medivation-llc-a-wholly-owned-subsidiary-of-pfizer-inc and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 38 studies since Jul 31, 2007.
- Feb 29, 2016Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02799745 · 227 enrolled · United States, Canada
- Sep 7, 2016Phase 3 study in Breast NeoplasmsPfizer · NCT02929576 · United States
- Sep 27, 2016Phase 4 study in Prostatic NeoplasmsAstellas Pharma · NCT02918968 · 206 enrolled · Japan
- Nov 7, 2016Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02960022 · 900 enrolled · United States, Argentina, Australia and more
- Aug 20, 2018Phase 4 study in Metastatic Castration Resistant Prostate CancerAstellas Pharma · NCT03641560 · 52 enrolled · India
- Dec 11, 2018Hinova Pharmaceuticals's first studies: 3 phase 1 studies in Metastatic Castration Resistant Prostate CancerNew to Hinova PharmaceuticalsHinova Pharmaceuticals · NCT03778047, NCT03776968, NCT03774056
- Feb 17, 2019Phase 3 study in MCRPCHinova Pharmaceuticals · NCT03851640 · 417 planned · China
- Feb 20, 2019hinova-pharmaceuticals-usa-inc's first study: phase 3 study in Prostate Cancer MetastaticNew to hinova-pharmaceuticals-usa-inchinova-pharmaceuticals-usa-inc · NCT03850795 · 104 enrolled · United States, Australia, Austria and more
- Aug 19, 2019Phase 3 study in Metastatic Hormone Sensitive Prostate CancerAstellas Pharma · NCT04076059 · 180 enrolled · China
- Sep 17, 2019Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT04094519 · 24 enrolled · Moldova, Republic of
- Mar 25, 2021Phase 3 study in Prostatic NeoplasmsPfizer · NCT04821622 · 599 enrolled · United States, Argentina, Australia and more
- Jul 28, 2021Applied Biology's first study: phase 3 study in COVID-19 Respiratory InfectionNew to Applied BiologyApplied Biology · NCT04986176 · 602 enrolled
- Dec 14, 2023Alessa Therapeutics's first study: phase 1 study in Prostate AdenocarcinomaNew to Alessa TherapeuticsAlessa Therapeutics · NCT06257693 · 45 planned · United States
- Aug 20, 2026Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT07783282 · 56 planned · Bulgaria
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT07783282
- Dec 30, 2028Primary completion: phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT06257693
- Jul 31, 2029Primary completion: phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02960022
TargetBeta
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07783282Prostatic Neoplasms · Bulgaria | 1 | Recruiting | Astellas Pharma | Apr 30, 2027 | 56 |
| NCT06257693Prostate Adenocarcinoma · United States | 1 | Recruiting | Alessa Therapeutics | Dec 30, 2028 | 45 |
| NCT04986176COVID-19 Respiratory Infection | 3 | UNKNOWN | Applied Biology | Dec 31, 2022 | 602 |
| NCT04821622Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Feb 18, 2026 | 599 |
| NCT04094519Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Astellas Pharma | Dec 27, 2020 | 24 |
| NCT04076059Metastatic Hormone Sensitive Prostate Cancer · China | 3 | Active, not recruiting | Astellas Pharma | Nov 18, 2022 | 180 |
| NCT03850795Prostate Cancer Metastatic · United States, Australia, Austria and more | 3 | Terminated | hinova-pharmaceuticals-usa-inc | Jun 28, 2024 | 104 |
| NCT03851640MCRPC · China | 3 | Recruiting | Hinova Pharmaceuticals | Sep 2025 | 417 |
| NCT03778047Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Hinova Pharmaceuticals | Oct 24, 2018 | 10 |
| NCT03776968Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Hinova Pharmaceuticals | Jan 15, 2018 | 47 |
| NCT03774056Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Hinova Pharmaceuticals | Sep 26, 2018 | 43 |
| NCT03641560Metastatic Castration Resistant Prostate Cancer · India | 4 | Completed | Astellas Pharma | Feb 20, 2024 | 52 |
| NCT02960022Prostatic Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Astellas Pharma | Jul 31, 2029 | 900 |
| NCT02918968Prostatic Neoplasms · Japan | 4 | Completed | Astellas Pharma | Mar 27, 2020 | 206 |
| NCT02929576Breast Neoplasms · United States | 3 | Withdrawn | Pfizer | Apr 2019 | 0 |
| NCT02799745Prostatic Neoplasms · United States, Canada | 2 | Completed | Astellas Pharma | Aug 28, 2020 | 227 |
| NCT02677896Metastatic Hormone Sensitive Prostate Cancer · United States, Argentina, Australia and more | 3 | Completed | Astellas Pharma | Oct 14, 2018 | 1,150 |
| NCT02528643Advanced Hepatocellular Carcinoma · United States, Canada, Hong Kong and more | 2 | Completed | Astellas Pharma | Oct 2, 2017 | 165 |
| NCT02441517Neoplasm Metastasis · United States | 4 | Terminated | Astellas Pharma | Mar 15, 2017 | 4 |
| NCT02384382Prostatic Neoplasms · United States | 2 | Completed | Pfizer | May 3, 2019 | 23 |
| NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Jan 31, 2023 | 1,068 |
| NCT02294461Bulbo-Spinal Atrophy, X-Linked · China, Hong Kong, South Korea and more | 3 | Completed | Astellas Pharma | Sep 20, 2015 | 395 |
| NCT02288247Neoplasm Metastasis · Austria, Belgium, Czechia and more | 3 | Completed | Astellas Pharma | Apr 30, 2020 | 688 |
| NCT02225093Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Astellas Pharma | Feb 3, 2014 | 12 |
| NCT02138799Drug-Drug Interaction (DDI) · Germany | 1 | Completed | Astellas Pharma | Sep 2013 | 28 |
| NCT02138162Severe Hepatic Impairment · Bulgaria | 1 | Completed | Astellas Pharma | Mar 2014 | 16 |
| NCT02124668Prostatic Neoplasms · Georgia, Russian Federation | 2 | Completed | Astellas Pharma | May 25, 2017 | 30 |
| NCT02116582Metastatic Castration-Resistant Prostate Cancer · Belgium, France, Germany and more | 4 | Completed | Astellas Pharma | May 8, 2016 | 215 |
| NCT02091960Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Astellas Pharma | Feb 28, 2017 | 103 |
| NCT02007512Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Sep 23, 2016 | 247 |
| NCT02003924Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Jun 28, 2017 | 1,401 |
| NCT01995513Prostatic Neoplasms · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 15, 2016 | 509 |
| NCT01977651Seizures · United States, Argentina, Australia and more | 4 | Completed | Astellas Pharma | Feb 1, 2016 | 424 |
| NCT01913379Healthy Subjects · France | 1 | Completed | Astellas Pharma | Dec 2011 | 41 |
| NCT01911741Healthy Subjects · Germany | 1 | Completed | Astellas Pharma | Mar 2013 | 55 |
| NCT01911728Pharmacokinetics of MDV3100 · South Africa | 1 | Completed | Astellas Pharma | Feb 21, 2012 | 14 |
| NCT01911715Healthy Subjects · Netherlands | 1 | Completed | Astellas Pharma | Jul 2011 | 6 |
| NCT01902251Prostatic Neoplasms · United States | 1 | Completed | Astellas Pharma | Oct 2013 | 27 |
| NCT01889238Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Mar 1, 2015 | 118 |
| NCT01901133Kidney Diseases · Moldova, Republic of | 1 | Completed | Astellas Pharma | Jan 2012 | 33 |
| NCT01664923Prostatic Neoplasms · United States | 2 | Completed | Pfizer | Feb 2015 | 396 |
| NCT01663415Neoplasms | 2 | Withdrawn | Astellas Pharma | Oct 2014 | 0 |
| NCT01650194Neoplasms · United States | 2 | Completed | Astellas Pharma | Jan 4, 2018 | 60 |
| NCT01597193Breast Neoplasms · United States | 1 | Completed | Pfizer | Dec 15, 2015 | 101 |
| NCT01547299Prostatic Neoplasms · United States, Canada | 2 | Completed | Pfizer | Nov 30, 2013 | 52 |
| NCT01565928Prostatic Neoplasms · United States | 1 | Completed | Pfizer | Jul 1, 2013 | 23 |
| NCT01534052Prostatic Neoplasms · United States, Moldova, Republic of, South Africa | 2 | Completed | Astellas Pharma | Apr 18, 2017 | 52 |
| NCT01302041Prostatic Neoplasms · Belgium, Czechia, Denmark and more | 2 | Completed | Astellas Pharma | Jul 29, 2012 | 67 |
| NCT01288911Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Astellas Pharma | Oct 19, 2014 | 375 |
| NCT01284920Prostatic Neoplasms · Japan | 2 | Completed | Astellas Pharma | Jul 12, 2012 | 47 |
| NCT01212991Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Pfizer | Sep 30, 2013 | 1,717 |
| NCT01091103Metastatic Progressive Castration-resistant Prostate Cancer · United States | 2 | Completed | Pfizer | Feb 29, 2012 | 60 |
| NCT00974311Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Sep 15, 2011 | 1,199 |
| NCT00510718Prostatic Neoplasms · United States | 1 | Completed | Pfizer | Dec 8, 2008 | 140 |
How it is read
Names in the registry
- “Enzalutamide”, 40 entries
- “enzalutamide”, 13 entries
- “MDV3100”, 8 entries
- “HC-1119”, 4 entries
- “HC1119”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 41 studies
- Neoplasms, 6 studies
- Breast Neoplasms, 5 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.